Telix and ANMI to commercialize prostate cancer imaging agent; create JV in the US
- Radiopharmaceuticals, Contrast Agents
- Joint Venture
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.